With a new use for an old compound, NeuroVive Pharmaceutical AB is positioning its cyclophilin inhibitor as a first-in-class treatment for NASH, adding the liver disease to the company’s repertoire of non-traditional mitochondrial disorders.
The move is the first step of the mitochondrial medicine company’s new strategy to divide its portfolio into two branches: one for common diseases involving mitochondrial dysfunction, the other for rare genetic diseases of mitochondrial origin.
Last month, NeuroVive announced that its preclinical compound NV556 prevented fibrosis in an animal model of non-alcoholic steatohepatitis (NASH). The compound is a mitochondria-stabilizing cyclophilin inhibitor designed to protect the liver from oxidative damage and fibrosis. NeuroVive regained rights to NV556, formerly NVP018, in October from Arbutus Biopharma Corp., which discontinued development of the agent for hepatitis B (HBV).
|BioCentury Product Profile|
|Concept||Liver-targeted, broad-spectrum cyclophilin inhibitor that stabilizes mitochondria to prevent hepatocyte cell death|
|Disease||Non-alcoholic steatohepatitis (NASH)|
|Competition||Anti-inflammatory agents; hormone receptor modulators|